查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1861573

周邊動脈疾病治療市場依產品類型、適應症、最終用戶及給藥途徑分類－2025-2032年全球預測

Peripheral Arterial Disease Therapeutics Market by Product Type, Indication, End User, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，周邊動脈疾病治療市場將成長至 103 億美元，複合年成長率為 9.06%。

關鍵市場統計數據
基準年 2024 51.4億美元
預計年份：2025年 56億美元
預測年份 2032 103億美元
複合年成長率 (%) 9.06%

周邊動脈疾病藥物的全面概述：影響治療路徑和相關人員決策的臨床、營運和商業性因素框架

周邊動脈疾病涉及血管病理學、治療方法創新和不斷變化的醫療服務模式等許多複雜因素。本執行摘要綜合了多學科的證據，闡明了臨床實踐、法規環境和商業策略之間的交集。以下重點介紹從傳統藥物治療到器械介入治療的各種治療方法，並將這些進展置於醫療系統優先事項和以患者為中心的治療結果的背景下進行說明。

肢體缺血和間歇性跛行的臨床負擔持續推動對現有藥物和新一代治療方法的需求。因此，臨床醫生和支付方越來越重視從手術療效、長期肢體挽救和心血管風險降低等方面評估干預措施。此外，患者的治療流程通常包括門診護理路徑、綜合創傷護理以及血管團隊協作，這些流程強調功能恢復和生存指標。鑑於這些現實情況，相關人員必須整合臨床證據、操作可行性和不斷變化的報銷模式，以最佳化治療方法的應用和患者預後。

程序創新、藥物進步和數位化診療路徑如何共同重新定義周邊動脈疾病的治療標準和長期管理

臨床實務與科技的融合正在改變周邊動脈疾病的診斷、治療和管理方式。影像學、導管介入術和輔助器械的最新進展推動了微創血管內治療技術的快速發展。同時，人們也重新關注藥物治療策略，不再只限於緩解症狀，而是致力於降低重大心血管事件的發生率，進而重塑了不同醫療機構的治療目標。

同時，數位醫療和遠端監測正在變革術後追蹤和慢性病管理。遠端醫療支援的血管診所和穿戴式動態血流監測設備與傳統血管實驗室相輔相成，能夠早期發現病情惡化並提供個人化復健方案。此外，再生醫學和生物目標的臨床研發正在加速推進，並有望為再灌注治療選擇有限的患者開闢新的治療途徑。最後，某些手術的治療擴大在門診進行，這提升了門診手術中心和專科診所作為醫療服務場所的策略重要性。這些因素共同推動著以價值、病患體驗和長期療效為優先的整合式醫療模式的發展。

預計隨著2025年美國關稅調整重塑治療生態系統的成本結構和業務永續營運，供應鏈調整、籌資策略和產品設計都將發生變化。

預計美國2025年關稅政策的變化可能會影響周邊動脈疾病治療生態系統的多個環節，相關人員已開始為各種連鎖反應做好準備。對進口醫療設備、藥品和中間組件徵收關稅可能會增加特種導管、藥物釋放型球囊和診斷成像設備等設備的到岸成本。因此，製造商和醫療系統可能會重新評估籌資策略，並尋求透過使用替代供應商、近岸外包和加快生產本地化來降低風險。

此外，關稅還可能影響醫院和門診手術中心的供應鏈時序和庫存策略。短期內，採購部門可能會增加緩衝庫存或重新談判供應契約，以確保關鍵耗材的穩定供應。長期來看，製造商可能會重新評估定價模式或遷移製造地，這將影響採購週期和設施升級的資本規劃。從研發角度來看，關稅帶來的成本壓力可能會促使投資重點轉向高效節能的技術和採用抗關稅組件的模組化設備設計。最後，監管機構和支付方的應對措施也將不斷調整，以確保醫療服務的可負擔性和可及性，並促進各方合作，在不降低臨床標準的舉措，維持醫療服務的連續性。

整合產品子類別、臨床適應症、醫療服務管道和給藥途徑等因素的策略性細分洞察，對於指導產品開發和商業化選擇至關重要。

深入了解患者、產品和通路細分對於協調研發和商業化策略至關重要。產品類型涵蓋抗凝血劑、抗血小板藥物、溶栓劑和血管擴張劑。抗凝血劑又細分為直介面服抗凝血劑、肝素和Warfarin；抗血小板藥物包括阿斯匹靈、Clopidogrel和替格瑞洛；溶栓劑包括組織型胞漿素原原活化劑 (t-PA) 和尿激酶；血管擴張劑則以Cilostazol和Pentoxifylline鹼為代表。這些差異會影響臨床決策、處方集安排和術後管理，因為每個亞類藥物都具有獨特的動態、監測要求和交互作用特徵。

基於適應症的分類區分了嚴重肢體缺血和間歇性跛行，二者在疾病進程、治療緊迫性和多學科協作需求方面存在顯著差異。終端使用者管道涵蓋門診手術中心、醫院和專科診所，而地點選擇會影響設備選擇、人員配備模式、報銷途徑和住院時長。此外，給藥途徑（口服或腸外給藥）也與依從性、門診可行性以及監測和給藥的資源分配等因素密切相關。整合這些細分維度，有助於相關人員優先考慮臨床開發項目、最佳化訊息，並制定能夠滿足臨床醫生、支付方和患者不同需求的准入策略。

美洲、歐洲、中東和非洲以及亞太地區的區域特徵和戰略意義，決定了監管方法、證據要求和進入策略。

區域趨勢對臨床實踐、監管預期和供應鏈結構有著深遠的影響。在美洲，臨床指引日益強調在關注肢體介入的同時，也要注重綜合性的心血管風險降低；而醫療系統則需要在專科醫生數量和不斷成長的門診手術量之間尋求平衡。此外，該地區的支付模式也存在顯著差異，這影響著新型治療方法的可及性和納入健保處方箋的時間。因此，優先考慮真實世界證據生成和以支付方為中心的衛生經濟學論證的策略，將在商業性談判中獲得支持。

在歐洲、中東和非洲地區，監管協調和多樣化的報銷途徑正在影響打入市場策略和臨床應用率。在許多市場，監管機構強調長期治療效果和成本效益數據，這延長了療法廣泛應用的時間，同時也為那些能夠保肢和改善心血管功能的治療方法創造了永續的價值提案。同時，亞太市場的特點是微創手術的快速普及、介入治療能力的不斷提升以及強勁的本土製造雄心，這些因素共同影響著定價動態和夥伴關係模式。了解這些區域特徵有助於申辦方合理安排市場進入順序、在地化證據生成，並最佳化製造地，以滿足當地的監管和商業性要求。

如何透過協作、拓展應用領域和提升生產韌性，將製藥、醫療設備和數位化解決方案策略融合起來，從而創造臨床和商業性價值

在周邊動脈疾病治療領域，各公司正採取多元化的策略，涵蓋漸進式創新、平台開發和策略聯盟。生物製藥公司著重研發差異化分子和兼具心血管獲益的聯合療法，以改善肢體功能並降低全身動脈粥樣硬化風險；而醫療設備製造商則專注於提升手術效率、輸送性和耐用性，並投資於新型塗層、導管設計以及與藥物治療方案相輔相成的組合產品。

在整個產業中，製藥公司與醫療設備製造商之間的合作日益普遍，從而能夠提供整合手術流程和藥物療法的綜合價值提案。此外，人們對數位療法和遠端監測的興趣日益濃厚，推動了與軟體和分析服務提供者的合作，以改善術後護理和病人參與。從企業策略角度來看，各公司在研發早期就優先考慮監管方面的應對措施，擴展臨床終點以納入功能和生活品質指標，並加強生產能力以降低關稅和供應鏈風險。總而言之，這些努力體現了從單一療法轉向綜合解決方案的趨勢。

產業領導者可採取切實可行的策略重點，以加強供應鏈、擴大證據產生並整合數位化醫療，從而加速治療方法推廣和支付方接受度。

產業領導者必須採取果斷行動，將科學進步和營運轉型轉化為永續的競爭優勢。首先，各機構應加快產生多學科證據，將手術創新與長期心血管和肢體預後聯繫起來，從而增強其對支付方和醫療系統的價值提案。其次，供應鏈多元化和區域化生產模式可以降低關稅波動風險，並提高對臨床醫生需求的應對力。投資於模組化設備設計以及從多個地區採購關鍵零件將增強營運韌性。

此外，企業應整合數位化健康解決方案，以支援藥物依從性、遠端監測和復原路徑，從而促進功能恢復並減少再入院率。儘早與監管機構和支付方接洽，並設計包含病患報告結果和衛生經濟學終點的臨床試驗，將有助於企業做好報銷準備。最後，制定反映產品亞型、適應症、臨床環境和給藥途徑細分的有針對性的商業策略，將最大限度地提高市場滲透率。開發與門診手術中心工作流程和醫院採購慣例相契合的銷售和臨床教育項目，將加速新型治療方法的應用。

我們採用方法嚴謹的方法，結合臨床醫師訪談、臨床文獻、監管分析和情境規劃，來檢驗我們的策略見解和建議。

本研究整合了第一手和第二手研究，旨在對周邊動脈疾病治療領域進行穩健且可重複的評估。第一手研究包括對臨床醫生、醫院採購人員、門診手術中心管理人員和臨床試驗研究人員進行結構化訪談，以收集有關藥物治療方案和醫療設備工作流程的真實世界資訊。這些定性研究結果輔以對公共臨床試驗註冊庫、同儕審查文獻、監管指導文件和衛生技術評估的分析，以確保臨床和監管方面的嚴謹性。

此分析架構整合了多軸細分方法、供應鏈和關稅風險情境規劃，以及涵蓋臨床結果、支付方要求和商業化路徑的主題三角驗證。資料檢驗過程包括將訪談結果與已發表的治療應用趨勢和醫療設備認證歷史進行交叉比對。最後，敏感性分析和專家評審完善了策略意義和建議，確保報告能夠為尋求在不斷發展的治療領域中開展研發、商業化和營運的循證路徑的決策者提供支援。

整合臨床進展、供應鏈壓力和策略要務，為周邊動脈疾病相關人員確定近期優先事項。

周邊動脈疾病的治療處於不斷發展的臨床科學、不斷變化的醫療環境和複雜的商業性壓力交匯點。該領域的特點是血管內技術的顯著進步、對降低全身風險的抗血栓策略的重新關注，以及對能夠證明肢體持久保全和改善患者功能的證據日益成長的需求。這些發展是在區域監管差異和潛在的關稅引發的供應鏈中斷的背景下進行的，因此需要製造商和醫療服務提供者採取積極主動且全面的策略應對措施。

簡而言之，相關人員，將最有能力應對未來幾年的挑戰。透過優先考慮多學科證據生成和適應性商業化模式，各機構可以將科學創新轉化為持續的臨床效益和商業性可行性。最終，這將為周邊動脈疾病患者建構一個更具韌性、以患者為中心的治療生態系統。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 針對嚴重肢體缺血患者血管生成路徑的新興基因療法
  • 藥物釋放型球囊和支架在治療周邊動脈狹窄的應用日益廣泛
  • 將數位監測設備整合到周邊動脈疾病管理中，用於持續評估肢體灌注狀態。
  • 擴大新型口服抗血栓藥物的使用範圍，以減少血管再阻塞並改善長期通暢性
  • 用於膝下血管重建手術的組織工程血管移植物的最新進展
  • 擴大旨在抑制周邊動脈疾病（PAD）中發炎介質的單株抗體的臨床開發平臺
  • 實施遠端醫療平台以進行遠距運動療法和患者依從性監測
  • 越來越關注利用基於生物標記的PAD患者亞型分層進行個人化醫療

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依產品類型周邊動脈疾病治療市場

  • 抗凝血劑
    • 口服抗凝血劑
    • 肝素
    • Warfarin
  • 抗血小板藥物
    • 阿斯匹靈
    • Clopidogrel
    • 替格瑞洛
  • 溶栓劑
    • 組織型胞漿素原原活化劑
    • 尿激酶
  • 血管擴張劑
    • Cilostazol
    • Pentoxifylline

第9章周邊動脈疾病藥物市場（依適應症分類）

  • 嚴重肢體缺血
  • 間歇性跛行

第10章周邊動脈疾病治療市場（依最終用戶分類）

  • 門診手術中心
  • 醫院
  • 專科診所

第11章周邊動脈疾病治療藥物市場（依給藥途徑分類）

  • 口服
  • 腸外

第12章 各地區周邊動脈疾病治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章周邊動脈疾病治療市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國周邊動脈疾病治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Medtronic plc
    • Terumo Corporation
    • Johnson & Johnson
    • Becton, Dickinson and Company
    • Koninklijke Philips NV
    • Cardiovascular Systems, Inc.
    • Merit Medical Systems, Inc.
    • Teleflex Incorporated
Product Code: MRR-69324464D29D

The Peripheral Arterial Disease Therapeutics Market is projected to grow by USD 10.30 billion at a CAGR of 9.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.14 billion
Estimated Year [2025] USD 5.60 billion
Forecast Year [2032] USD 10.30 billion
CAGR (%) 9.06%

An integrated overview of peripheral arterial disease therapeutics that frames clinical, operational, and commercial drivers shaping treatment pathways and stakeholder decisions

Peripheral arterial disease represents a complex intersection of vascular pathology, therapeutic innovation, and shifting care delivery models. This executive summary synthesizes multidisciplinary evidence to illuminate where clinical practice, regulatory environments, and commercial strategy converge. The narrative that follows focuses on therapeutic modalities ranging from classical pharmacotherapies to device-based interventions, and frames these developments against the backdrop of health system priorities and patient-centric outcomes.

The clinical burden of limb ischemia and intermittent claudication continues to drive demand for both established agents and next-generation therapeutics. Consequently, clinicians and payers increasingly evaluate interventions on procedural efficacy, long-term limb salvage, and cardiovascular risk reduction. Moreover, the patient journey now commonly involves outpatient pathways, integrated wound care, and coordinated vascular teams that emphasize functional recovery alongside survival metrics. Given these realities, stakeholders must integrate clinical evidence with operational feasibility and evolving reimbursement paradigms to optimize therapeutic adoption and patient outcomes.

How procedural innovation, pharmacologic evolution, and digital care pathways are jointly redefining standards of treatment and long-term management for peripheral arterial disease

Clinical practice and technology are converging to create transformative shifts in how peripheral arterial disease is diagnosed, treated, and managed. In recent years, minimally invasive endovascular techniques have advanced rapidly, supported by improvements in imaging, catheter technologies, and adjunctive devices. These procedural advances have coincided with a renewed focus on pharmacologic strategies that extend beyond symptom relief to reduce major adverse cardiovascular events, thereby reframing therapeutic objectives across care settings.

Concurrently, digital health and remote monitoring are changing post-procedural follow-up and chronic disease management. Telemedicine-facilitated vascular clinics and wearable-enabled gait and perfusion monitoring complement traditional vascular labs, enabling earlier detection of deterioration and tailored rehabilitation programs. At the same time, regenerative medicine and targeted biologics continue to progress through clinical development, promising alternative pathways for patients with limited revascularization options. Finally, care delivery has shifted toward ambulatory settings for selected procedures, increasing the strategic importance of ambulatory surgical centers and specialty clinics as sites of care. Together, these factors are driving integrated care models that prioritize value, patient experience, and longitudinal outcomes.

Anticipating supply chain adjustments, procurement strategies, and product design shifts as U S tariff changes in 2025 reshape cost dynamics and operational resilience in the therapeutic ecosystem

Changes in U.S. tariff policy projected for 2025 have the potential to affect multiple elements of the peripheral arterial disease therapeutic ecosystem, and stakeholders are already preparing for varied ripple effects. Tariffs on imported medical devices, pharmaceuticals, and intermediate components may increase landed costs for devices such as specialized catheters, drug-coated balloons, and diagnostic imaging equipment. As a result, manufacturers and health systems may reassess sourcing strategies, seeking to mitigate exposure through alternative suppliers, nearshoring, or accelerated localization of production.

Moreover, tariffs can influence the supply chain timing and inventory strategies adopted by hospitals and ambulatory surgical centers. In the near term, purchasing teams may expand buffer inventories or renegotiate supply contracts to stabilize access to critical consumables. Over time, manufacturers could revise pricing models or shift manufacturing footprints, which in turn would affect procurement cycles and capital planning for facility upgrades. From a research and development perspective, tariff-driven cost pressures may reorient investment priorities toward cost-efficient innovations and modular device designs that rely less on tariff-exposed components. Finally, regulatory and payer responses may evolve to address affordability and access, prompting collaborative initiatives to preserve continuity of care without compromising clinical standards.

Strategic segmentation insights that integrate product subclasses, clinical indications, care delivery channels, and administration routes to inform development and commercialization choices

A granular understanding of patient, product, and channel segmentation is essential to align research, development, and commercialization strategies. Product type considerations span anticoagulants, antiplatelet agents, thrombolytics, and vasodilators, with anticoagulants subdividing into direct oral anticoagulants, heparin, and warfarin while antiplatelet agents encompass aspirin, clopidogrel, and ticagrelor; thrombolytics include tissue plasminogen activator and urokinase, and vasodilators are typified by cilostazol and pentoxifylline. These distinctions influence clinical decision-making, formulary placement, and post-procedural management, since each subclass carries unique pharmacodynamics, monitoring requirements, and interaction profiles.

Indication-based segmentation discriminates between critical limb ischemia and intermittent claudication, which differ markedly in disease trajectory, therapeutic urgency, and multidisciplinary care needs. End-user channels range from ambulatory surgical centers to hospitals and specialty clinics, and the choice of setting impacts device selection, staffing models, reimbursement pathways, and length of stay. Finally, route of administration - oral versus parenteral - intersects with adherence considerations, outpatient feasibility, and resource allocation for monitoring and administration. By integrating these segmentation axes, stakeholders can prioritize clinical development programs, tailor marketing messages, and design access strategies that address the nuanced needs of clinicians, payers, and patients.

Regional contours and strategic implications across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate regulatory approaches, evidence needs, and access strategies

Regional dynamics exert a powerful influence on clinical practice, regulatory expectations, and supply chain architecture. In the Americas, clinical guidelines increasingly emphasize integrated cardiovascular risk reduction alongside limb-focused interventions, while health systems balance specialist capacity with growing outpatient procedural volumes. This region also exhibits significant heterogeneity in payer models, which affects formulary access and adoption timelines for novel therapies. Consequently, strategies that prioritize real-world evidence generation and payer-centric health economic dossiers will find traction in commercial conversations.

Across Europe, Middle East & Africa, regulatory harmonization and varying reimbursement pathways shape market entry strategies and clinical adoption rates. In many markets, authorities place a premium on long-term outcomes and cost-effectiveness data, which can lengthen time to wide adoption but also create durable value propositions for therapies that demonstrate limb salvage and cardiovascular benefit. In contrast, Asia-Pacific markets are characterized by rapid uptake of minimally invasive procedures, expanding interventional capacity, and strong domestic manufacturing ambitions, which together influence pricing dynamics and partnership models. Recognizing these regional contours allows sponsors to sequence market entry, localize evidence generation, and optimize manufacturing footprints to meet distinct regulatory and commercial requirements.

How pharmaceutical, medical device, and digital solution strategies are converging through partnerships, expanded endpoints, and manufacturing resilience to capture clinical and commercial value

Companies operating in the peripheral arterial disease therapeutic space are pursuing diversified strategies that span incremental innovation, platform development, and strategic partnerships. Biopharmaceutical firms emphasize differentiated molecules and composite cardiovascular benefit profiles that address both limb outcomes and systemic atherosclerotic risk. At the same time, medical device manufacturers focus on procedural efficiency, deliverability, and durability, investing in novel coatings, catheter design, and combination products that complement pharmacologic regimens.

Across the industry, collaboration between pharma and device players is increasingly common, enabling bundled value propositions that align procedural and medical management. Additionally, growing interest in digital therapeutics and remote monitoring has catalyzed partnerships with software and analytics providers to enhance post-procedural care and patient engagement. From a corporate strategy perspective, companies are prioritizing regulatory alignment early in development, expanding clinical endpoints to include functional and quality-of-life measures, and pursuing manufacturing resilience to mitigate tariff and supply chain risks. These approaches collectively reflect a shift toward holistic solutions that extend beyond single-modality interventions.

Actionable strategic priorities for industry leaders to fortify supply chains, amplify evidence generation, and integrate digital care to accelerate therapy adoption and payer acceptance

Industry leaders must act decisively to convert scientific advances and operational shifts into sustainable competitive advantage. First, organizations should accelerate cross-disciplinary evidence generation that links procedural innovation with long-term cardiovascular and limb outcomes, thereby strengthening value propositions for payers and health systems. Secondly, supply chain diversification and regional manufacturing options will reduce exposure to tariff volatility and improve responsiveness to clinician demand. Investing in modular device designs and procuring critical components from multiple geographies will enhance operational resilience.

Furthermore, companies should integrate digital health solutions to support adherence, remote monitoring, and rehabilitation pathways that improve functional recovery and reduce readmissions. Engaging regulators and payers early, and designing trials that incorporate patient-reported outcomes and health economic endpoints, will facilitate reimbursement readiness. Finally, targeted commercial strategies that reflect segmentation across product subtypes, indications, care settings, and routes of administration will maximize uptake; aligning sales and clinical education programs to ambulatory surgical center workflows and hospital procurement practices will accelerate diffusion of novel therapies.

A methodologically rigorous approach combining clinician interviews, clinical literature, regulatory analysis, and scenario planning to validate strategic insights and recommendations

This research synthesizes primary and secondary sources to deliver a robust, reproducible assessment of the peripheral arterial disease therapeutics landscape. Primary research included structured interviews with clinicians, hospital procurement leaders, ambulatory surgical center administrators, and clinical trial investigators to capture frontline experiences with pharmacologic regimens and device workflows. These qualitative insights were supplemented with analyses of publicly available clinical trial registries, peer-reviewed literature, regulatory guidance documents, and health technology assessments to ensure clinical and regulatory rigor.

The analytical framework incorporates a multi-axis segmentation approach, scenario planning for supply chain and tariff exposures, and thematic triangulation across clinical outcomes, payer requirements, and commercial pathways. Data validation processes involved cross-referencing interview findings with published procedure utilization trends and device approval histories. Finally, sensitivity checks and expert reviews helped refine strategic implications and recommendations, ensuring the report supports decision-makers seeking evidence-based pathways for development, commercialization, and operations within this evolving therapeutic area.

Synthesis of clinical advances, supply chain pressures, and strategic imperatives that together define the near-term priorities for peripheral arterial disease stakeholders

Peripheral arterial disease therapeutics sits at the intersection of evolving clinical science, changing care settings, and complex commercial pressures. The landscape is characterized by meaningful advances in endovascular technology, renewed emphasis on antithrombotic strategies that reduce systemic risk, and increasing demand for evidence that demonstrates durable limb salvage and improved patient function. These developments occur against a backdrop of regional regulatory diversity and potential tariff-driven supply chain disruptions, which together require proactive and integrated strategic responses from manufacturers and providers.

In sum, stakeholders that align product development with payer evidence needs, invest in supply chain agility, and leverage digital care to enhance outcomes will be best positioned to navigate the coming years. By prioritizing multidisciplinary evidence generation and adaptive commercialization models, organizations can translate scientific innovation into sustained clinical benefit and commercial viability. The result will be a more resilient, patient-centered therapeutic ecosystem for individuals living with peripheral arterial disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of gene therapy targeting angiogenesis pathways in critical limb ischemia patients
  • 5.2. Rising adoption of drug-coated balloons and stents in peripheral arterial stenosis interventions
  • 5.3. Integration of digital monitoring devices for continuous limb perfusion assessment in PAD management
  • 5.4. Expansion of novel oral antithrombotic agents to reduce restenosis and improve long-term patency
  • 5.5. Advances in tissue-engineered vascular grafts for below-the-knee revascularization procedures
  • 5.6. Growing clinical pipeline of monoclonal antibodies aimed at inhibiting inflammatory mediators in PAD
  • 5.7. Implementation of telehealth platforms for remote exercise therapy and patient adherence monitoring
  • 5.8. Increasing focus on personalized medicine using biomarker-driven stratification of PAD patient subtypes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peripheral Arterial Disease Therapeutics Market, by Product Type

  • 8.1. Anticoagulants
    • 8.1.1. Direct Oral Anticoagulants
    • 8.1.2. Heparin
    • 8.1.3. Warfarin
  • 8.2. Antiplatelet Agents
    • 8.2.1. Aspirin
    • 8.2.2. Clopidogrel
    • 8.2.3. Ticagrelor
  • 8.3. Thrombolytics
    • 8.3.1. Tissue Plasminogen Activator
    • 8.3.2. Urokinase
  • 8.4. Vasodilators
    • 8.4.1. Cilostazol
    • 8.4.2. Pentoxifylline

9. Peripheral Arterial Disease Therapeutics Market, by Indication

  • 9.1. Critical Limb Ischemia
  • 9.2. Intermittent Claudication

10. Peripheral Arterial Disease Therapeutics Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Peripheral Arterial Disease Therapeutics Market, by Route Of Administration

  • 11.1. Oral
  • 11.2. Parenteral

12. Peripheral Arterial Disease Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Peripheral Arterial Disease Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Peripheral Arterial Disease Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. Boston Scientific Corporation
    • 15.3.3. Medtronic plc
    • 15.3.4. Terumo Corporation
    • 15.3.5. Johnson & Johnson
    • 15.3.6. Becton, Dickinson and Company
    • 15.3.7. Koninklijke Philips N.V.
    • 15.3.8. Cardiovascular Systems, Inc.
    • 15.3.9. Merit Medical Systems, Inc.
    • 15.3.10. Teleflex Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2